




The relative strengths and weaknesses of Sonoma Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sonoma Pharmaceuticals Inc compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 68% points. The greatest weakness of Sonoma Pharmaceuticals Inc is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 47% points.

The company's Economic Capital Ratio, given in the ranking table, is 233%, being 20% points above the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	13,798
Cost of Goods Sold	8,795
Intangible Assets	0
Liabilities, Current	3,717
Liabilities, Non-Current	162
Other Assets	1,945
Other Compr. Net Income	894
Other Expenses	-33
Other Liabilities	4,375
Other Net Income	-614
Other Revenues	13,272
Property and Equipment	488
Research and Development	207
Selling, General and Administrative Expense	8,840

Output Variable	Value in 1000 USD
Assets	16,231
Liabilities	8,254
Expenses	17,809
Revenues	13,272
Stockholders Equity	7,977
Net Income	-5,151
Comprehensive Net Income	-4,704
BaseVar	28,537
ECR before LimitedLiability	104%
Economic Capital Ratio	233%